Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06820268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: NovaOnco Therapeutics Co., Ltd. to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    • Primary endpoints: details revised at 1 of 2 entries
    • Eligibility criteria expanded, about 33 words
  2. Trial status: Enrolling by Invitation to Recruiting
    • Interventions: XS-04 tablet (Other) to XS-04 tablet (Drug)
    • Site details revised at 4 of 4 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
Trial Details
NCT Number NCT06820268
Lead Sponsor Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions
(from sponsor)		 B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Related terms Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Myelodysplastic Syndromes
Enrollment 168 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov